<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39323274</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1660-9379</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>888</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Revue medicale suisse</Title><ISOAbbreviation>Rev Med Suisse</ISOAbbreviation></Journal><ArticleTitle>[New developments in the diagnosis and treatment of community-acquired pneumonia].</ArticleTitle><Pagination><StartPage>1714</StartPage><EndPage>1717</EndPage><MedlinePgn>1714-1717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.53738/REVMED.2024.20.888.1714</ELocationID><Abstract><AbstractText>Community acquired pneumonia is a well-known entity in internal medicine. It represents 1.2 cases per 1000 inhabitants every year, and up to 14 cases per 100 inhabitants in people older than 65 years old. Despite our exposition to the disease almost daily, it is still the leading cause of death related to an infection. In 2019, The American Thoracic Society proposed a revision of its guidelines, especially concerning the diagnosis and the treatment of community acquired pneumonia. It is the latest academic society revision. Further-more, the SARS-CoV-2 pandemia has extended our knowledge of pulmonary infection and brought an adaptation of our practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Velasquez</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service de médecine de premier recours, Département de médecine communautaire, Hôpitaux universitaires, de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>El Maazi</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de médecine de premier recours, Département de médecine communautaire, Hôpitaux universitaires, de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergeron</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de pneumologie, Département de médecine interne, Hôpitaux universitaires de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosetti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service des maladies infectieuses, Département de médecine interne, Hôpitaux universitaires de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service des maladies infectieuses, Département de médecine interne, Hôpitaux universitaires de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillabert</LastName><ForeName>Cédric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre médical Lancy, Route de Chancy 59C, 1213 Petit-Lancy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevallier-Lugon</LastName><ForeName>Chloé</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de médecine de premier recours, Département de médecine communautaire, Hôpitaux universitaires, de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalbert</LastName><ForeName>Bénédicte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de médecine de premier recours, Département de médecine communautaire, Hôpitaux universitaires, de Genève, 1211 Genève 14.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Nouveautés dans le diagnostic et le traitement de la pneumonie acquise en communauté.</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Rev Med Suisse</MedlineTA><NlmUniqueID>101219148</NlmUniqueID><ISSNLinking>1660-9379</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017714" MajorTopicYN="Y">Community-Acquired Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>La pneumonie acquise en communauté (PAC) est une entité bien connue de la médecine interne générale. En effet, elle représente 1,2 cas pour 1000 habitants chaque année, et jusqu’à 14 cas pour 1000 habitants chez les plus de 65 ans. Elle reste la première cause de mortalité liée à une infection et est responsable d’une morbidité importante. En 2019, l’American Thoracic Society propose une révision de ses guidelines, notamment sur le diagnostic et les traitements de la PAC. Il s’agit de la dernière revue de société savante. De plus, la pandémie de SARS-CoV-2 a enrichi notre compréhension des infections pulmonaires et a conduit à une adaptation de nos pratiques.</AbstractText></OtherAbstract><CoiStatement>Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323274</ArticleId><ArticleId IdType="doi">10.53738/REVMED.2024.20.888.1714</ArticleId><ArticleId IdType="pii">RMS0888-008</ArticleId></ArticleIdList></PubmedData></PubmedArticle>